Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
08 August 2022 - 9:00PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission it is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
appointed Christopher L. Jordan as Vice President, Regulatory
Affairs.
“We are pleased to announce the addition of Christopher Jordan
to our leadership team as VP of Regulatory Affairs. Christopher
brings over 30 years of pharmaceutical experience across various
stages of product development. Some on our management team have had
the pleasure of working with Christopher several years ago at
Endocyte and Novartis where he recently led the regulatory strategy
and execution of the FDA approval of Pluvicto and EMA submission of
that agent. His vast knowledge in the oncology field will be a
great addition to the team as we continue to development ONC201 and
our other oncology pipeline products,” said Mike Sherman, Chief
Executive Officer of Chimerix.
“I am excited to be joining the Chimerix team as we advance a
next generation of oncology therapies targeting areas of high unmet
need. In particular, ONC201 has demonstrated rare single-agent
activity in H3 K27M-mutant glioma which is a devasting disease with
a poor prognosis. I am energized to work with FDA and other
regulatory agencies to help bring this potential medicine to
patients as quickly as possible,” said Christopher Jordan, Vice
President, Regulatory Affairs at Chimerix.
Mr. Jordan joins Chimerix from Novartis where he was most
recently Senior Global Program Regulatory Director. Prior to that
role he was Americas Head of Regulatory Affairs at Novartis’s
wholly-owned subsidiary, Advanced Accelerator Applications. Prior
to Novartis, Mr. Jordan was the Vice President, Regulatory Affairs
at Endocyte, Inc, an oncology-focused biotechnology company. Mr.
Jordan began his career at Eli Lilly and Company in a range of
product development and regulatory affairs roles. He also served as
an adjunct professor of regulatory affairs at George Washington
University from 2017 to 2019.
Mr. Jordan earned his Master of Science in Health Science in
Regulatory Affairs from George Washington University, and Bachelor
Science in Chemistry from Purdue University.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws. You can identify these
statements by our use of such words as “will,” “expects,” “plans,”
“intends,” “believes,” and similar expressions that do not relate
to historical matters. Forward-looking statements in this press
release include, but are not limited to, statements, inferences,
beliefs or expectations regarding: the Company’s plans, objectives
and intentions that are not historical facts generally. These
statements reflect the current intent, beliefs and expectations of
the Company’s management. They involve known and unknown risks,
uncertainties and other factors that may cause future events,
including the Company’s performance and results to differ
materially from those expressed or implied by the forward-looking
statements. Factors that may cause actual future events to differ
from those in the forward-looking statements. See also the factors
described under the heading “Item 1A -- Risk Factors” in our Annual
Report on Form 10-K for the year ended December 31, 2022, and in
our Quarterly Report on Form 10-Q for the quarter ended March 31,
2022, or as otherwise described in our other public filings. The
Company’s results may also be affected by factors of which the
Company is not currently aware. The Company may not update these
forward-looking statements, even though its situation may change in
the future, unless it has obligations under the federal securities
laws to update and disclose material developments related to
previously disclosed information.
CONTACT:Investor
Relations: Michelle
LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024